Latest Manufacturing News

Titomic has set 30 November 2026 as its current target to complete a proposed move of its parent company from Australia to the United States. The ASX listing would remain, but investors would hold CHESS Depositary Interests in the new US entity if shareholders, the Court and other conditions approve the scheme.

Mesoblast has secured FDA approval to add a new potency assay to commercial release and stability testing for Ryoncil, its approved cell therapy for paediatric graft-versus-host disease. The regulatory decision supports tighter monitoring as manufacturing processes evolve, but the company disclosed no direct financial impact or clinical outcome data.

Zimi has secured an exclusive three-year distribution agreement with Directed for retail, direct-to-consumer and direct-to-business sales across Australia and New Zealand. The deal gives its next-generation Matter devices access to more than 10,000 retail outlets, although commercial terms and guaranteed sales volumes remain undisclosed.

Vection Technologies has signed reciprocal five-year reseller agreements with Xerox, opening a potential Western European channel for its conversational AI, digital human, kiosk and XR technologies. The opportunity is strategically notable, but the agreements contain no minimum volumes, pricing or committed revenue.

BluGlass has agreed an A$8.0 million R&D-backed loan with Rockford, refinancing its existing Radium facility and adding about A$5.5 million of liquidity. The funding gives the laser developer more room to scale, but carries a 16.5% interest rate and repayment obligations tied to future tax refunds.

Advanced Engineered Materials is forecasting a sharp lift in second-half sales as its Quebec high-purity alumina operation moves from qualification work towards commercial production. The larger prize is a possible 6,000-tonne-per-year expansion, but that plan still depends on feasibility, financing and final investment approval.

Delorean Corporation and Opal have completed the concept stage for a proposed anaerobic digestion facility at Opal’s Maryvale Mill in Victoria. The project could replace natural gas used by the mill’s rotary lime kiln, but still requires further engineering, commercial work and a final investment decision.

Synertec has raised its FY27 revenue guidance by $8.0 million to $8.3 million, pointing to stronger contract conversion and visibility across its Engineering and Powerhouse businesses. The upgrade follows the $45.5 million ANSTO nuclear medicine manufacturing contract, but covers revenue only and not earnings or cash flow.

Patrys has dosed the first participants in the Phase 1a trial of RLS-2202, moving its intravenous quetiapine formulation into human clinical evaluation. The next test comes in October, when an independent safety committee will decide whether the program can advance to Cohort 2.

Nufarm expects FY26 underlying EBITDA to rise about 25% at the midpoint of its $370 million to $380 million range, while leverage falls from 2.7 times to approximately 2.0 times. The improvement comes alongside a sweeping cost-reduction program, but restructuring charges of up to $110 million post tax remain in the numbers.

Astron Limited (ASX:ATR) says its Donald rare earths and mineral sands project is construction-ready, with a $759 million Phase 1 pre-tax NPV and first production targeted for 2028. The unresolved question is whether debt financing can convert the project’s strong study economics into a final investment decision.

AdAlta has secured a formal US FDA pre-IND meeting for EW-001, moving its mesothelioma CAR-T therapy into a critical regulatory review. The November meeting will test the company’s Australian manufacturing, remaining studies and proposed Phase 1 trial before the more expensive stages of development begin.